BURNABY, BC, Sept. 7 /CNW/ - Welichem Biotech Inc. ("WBI" or the
"Company") (TSX-V: WBI - News) is very pleased to report that the Phase I
Clinical Trials of the Company's anti-psoriasis drug candidate, WBI-1001, are
running as planned in Montreal, Quebec. The trials consist of six separate
cohorts. All six patients in Cohort I have been treated with WBI-1001 for at
least fourteen days and none has experienced any adverse side effects.
Patients for Cohort II, in which the dosage level will be increased, are now
The Company notes that Mr. Andrew Baren, the company's investor relations
manager, recently left Welichem to pursue personal interests. We thank him for
his efforts on our behalf and we wish him well.
The Company seeks Safe Harbour.
About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune diseases and cancer.
ON BEHALF OF THE BOARD
York Yingping Guo
President and Chief Executive Officer
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. This press release contains forward-looking statements that include
our belief as to the potential of our products. Certain risks and
uncertainties such as our ability to successfully commercialize the products
could cause the Company's actual results to differ materially from those in
the forward-looking statements.
For further information:
For further information: York Yingping Guo, Tel.: (604) 432-1703, Email:
email@example.com; Yan Chen, Business Development Manager, Tel.: (604)
432-1703, Email: firstname.lastname@example.org